| ¿µ¹® | anaphylaxis | ÇÑ±Û | ¾Æ³ªÇʶô½Ã½º, °ú¹ÎÁõ |
|---|---|---|---|
| ¼³¸í | ¾Æ³ªÇʶô½Ã½º¶ó´Â ¸»Àº Á¦ 1Çü °ú¹Î¹ÝÀÀ°ú °°Àº ¸»·Î ¿Ü°èÀÇ ¹°Áú¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀÌ Áö³ªÄ¡°Ô Ç×ÁøµÇ¾î ÀÖ´Â º´ÀûÀÎ »óŸ¦ ¸»ÇÑ´Ù. ¸é¿ªÀ̶õ ¿ÜºÎ¹°Áú¿¡ ´ëÇÑ ¹æ¾î¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ¼¼Æ÷µéÀÇ È°µ¿À» ÀǹÌÇϸç, ¿©±â¿¡´Â Ç×üÀÇ Çü¼º, ¼¼Æ÷µéÀÇ Æ÷½ÄÀÛ¿ë(¿ÜºÎ¿¡¼ µé¾î¿Â ¹°ÁúÀ» ¸é¿ª±â´ÉÀ» ÇÏ´Â ¼¼Æ÷°¡ Àâ¾Æ¸Ô´Â °Í)µîÀÌ Æ÷ÇԵȴÙ. Ç×üÀÇ Çü¼ºÀº ¿ÜºÎ·ÎºÎÅÍ µé¾î¿Â ¹°ÁúÀ» ¿ì¼± Å«Æ÷½Ä¼¼Æ÷ µîÀÌ Æ÷½ÄÀ» Çϰí À̰Ϳ¡ ´ëÇÑ Á¤º¸¸¦ T-¸²ÇÁ±¸¿¡°Ô Àü´ÞÇϰí T-¸²ÇÁ±¸´Â ÀÌ Á¤º¸¸¦ ó¸®ÇÏ¿© Áý¾àµÈ Á¤º¸¸¦ B-¸²ÇÁ±¸¿¡°Ô Àü´ÞÇϸç ÀÌ ¼¼Æ÷·Î ÇÏ¿©±Ý ±× ¹°Áú ¿¡ ´ëÇÑ Ç×ü¸¦ »ý¼ºÇÏ°Ô ÇÑ´Ù. Ç×ü´Â ¿ÜºÎÀÇ ¹°Áú°ú Á¤È®È÷ °áÇÕÇÏ¿© ¿ÜºÎÀÇ ¹°ÁúÀÇ È°¼ºÈ¸¦ ¾ø¾Ö´Â ¹°ÁúÀÌ´Ù. ÀÌ·¸°Ô Çü¼ºµÈ Ç×üÁß¿¡¼ IgE¿¡ ºÎÂøµÉ ¼ö ÀÖ´Â, Áï ÀÌ¹Ì Ç×ü IgE°¡ Çü¼ºµÈ(ÀÌ·¸°Ô µÇ±â À§Çؼ´Â ±× ¹°ÁúÀÌ ÀÌÀü¿¡ ÇÑ ¹ø ¸ö¼Ó¿¡ µé¾î ¿Ô¾î¾ß ÇÑ´Ù) ¹°ÁúÀÌ È÷½ºÅ¸¹Î µîÀÇ ¿©·¯ ¹°ÁúÀÌ ³ª¿À°Ô µÇ°í ÀÌ·± ¹°Áúµé¿¡ ÀÇÇØ¼ »ý±â´Â ¿©·¯ °¡Áö ½Åü¿¡ ÇØ·Î¿î ¹ÝÀÀÀÌ »ý°Ü³´Ù. ±×·¡¼ ÇÊ¿ä ÀÌ»óÀ¸·Î °ú¹ÎÇÑ ÀÌ·¯ÇÑ ÇüÅÂÀÇ ¸é¿ªÀÛ¿ëÀ» °ÅÄ¡´Â ¹ÝÀÀÀ» ¾Æ´ÏÇʶô½Ã½º¶ó ÇÑ´Ù. |
||
| ¿µ¹® | rheumatoid factor | ÇÑ±Û | ·ù¸¶Æ¼½º ÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | IgGÀÇ FcºÎÀ§¿¡ ÀÖ´Â Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼ ÀüÇüÀûÀÎ ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) ȯÀÚÀÇ 80%¿¡¼ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀÚ´Â IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁÖ·Î IgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇÏ´Â ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù |
||
| ¿µ¹® | growth factor | ÇÑ±Û | ¼ºÀåÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ ºÐÈ ¹× ¼ºÀå¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú. ¼ºÀåÀÎÀÚ´Â Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ žÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| ECFA, ECF-A | eosinophilic chemotactic factor of anaphylaxis |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| EDF | eosinophil differentiation factor; erythroid differentiation factor; extradural fluid |
| ECF-A | eosinophil chemotactic factor of anaphylaxis |
|---|---|
| ECF | Eosinophil chemotactic factor |
| ECA | Eosinophil chemotactic activity |
| EO-CSF | eosinophil colony stimulating factor |
| ACA | Active cutaneous anaphylaxis |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| eosinophil chemotactic factor of anaphylaxis | A peptide (MW 500 to 600) that is chemotactic for eosinophilic leukocytes and is released from disrupted mast cells. (05 Mar 2000) |
|---|
| chemotactic factors, eosinophil | Cytotaxins liberated from normal or invading cells that specifically attract eosinophils; they may be complement fragments, lymphokines, neutrophil products, histamine or other; the best known is the tetrapeptide ecf-a, released mainly by mast cells. (12 Dec 1998) |
|---|---|
| eosinophil chemotactic peptide | <protein> Tetrapeptides (of which two are identified: VGSE and AGSE) released by mast cells and that are said to both attract and activate eosinophils. (18 Nov 1997) |
| monocyte chemotactic and activating factor | Cytokine of the C C subfamily, co induced with IL-8 on stimulation of endothelial cells, fibroblasts or monocytes that activates and is chemotactic for, monocytes. A chemokine. (18 Nov 1997) |
| monocyte derived neutrophil chemotactic factor | <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes. It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4. Acronym: IL-8 (12 Dec 1998) |
| complement chemotactic factor | The activated complex of the fifth, sixth, and seventh components of complement (C567) which induces chemotaxis in the case of polymorphonuclear leukocytes. (05 Mar 2000) |
| slow-reacting factor of anaphylaxis | Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules. Compare: peptidyl leukotrienes. Synonym: slow-reacting factor of anaphylaxis. (05 Mar 2000) |
| absolute eosinophil count | <haematology, investigation> A measurement (cells per microlitre) of the number of eosinophils in a blood specimen. This measurement is useful in the evaluation of autoimmune disease, allergies, eczema, leukaemia, asthma and hay fever. Normal absolute eosinophil counts are less than 350 cells/mcl (microlitre). (27 Sep 1997) |
| chemotactic | A response of motile cells or organisms in which the direction of movement is affected by the gradient of a diffusible substance. Differs from chemokinesis in that the gradient alters probability of motion in one direction only, rather than rate or frequency of random motion. (18 Nov 1997) |
| chemotactic factors | Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult. (12 Dec 1998) |
| chemotactic factors, macrophage | Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other. (12 Dec 1998) |
| chemotactic protein methylesterase | <enzyme> Demethylates methyl-accepting chemotaxis proteins Registry number: EC 3.1.1.- Synonym: chemotactic methylesterase, carboxymethylesterase of chemotaxis, cheb methylesterase (26 Jun 1999) |
| eosinophil | Polymorphonuclear leucocyte (granulocyte) of the myeloid series, of which the granules stain red with eosin. Phagocytic, particularly associated with helminth infections and with hypersensitivity. (18 Nov 1997) |
| eosinophil adenoma | <endocrinology, oncology, tumour> A benign tumour, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumours may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhoea. (25 Jun 1999) |
| eosinophil cationic protein | <protein> Arginine rich protein (21 kD) in granules of eosinophils, that damages schistosomula in vitro. Not the same as the MBP (major basic protein) of the granules. (18 Nov 1997) |
| eosinophil count | A measurement (cells per microlitre) of the number of eosinophils in a blood specimen. This measurement, also called the absolute eosinophil count, is useful in the evaluation of autoimmune disease, allergies, eczema, leukaemia, asthma and hay fever. Normal absolute eosinophil counts are less than 350 cells/mcl (microlitre). (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|